Literature DB >> 19816733

[Pseudo-arthroses].

J Meiners1, U Gerlach, S Mägerlein, C Jürgens, M Faschingbauer.   

Abstract

Pseudo-arthroses are disorders of fracture healing after conservative or operative treatment of fractures which are older than 6 months. Decisive for a targeted therapy is a differentiation between aseptic and septic or atrophic, oligotrophic or hypertrophic pseudo-arthrosis. The operative principals include revitalization of atrophic bone fragments, stabilizing reosteosynthesis for instability and the treatment of infection by transformation of a septic into a stabilized or aseptic pseudo-arthrosis.

Entities:  

Mesh:

Year:  2009        PMID: 19816733     DOI: 10.1007/s00104-009-1779-8

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  3 in total

Review 1.  Bone graft and bone graft substitutes: a review of current technology and applications.

Authors:  C J Damien; J R Parsons
Journal:  J Appl Biomater       Date:  1991

2.  [Incidence of osteomyelitis after osteosynthesis].

Authors:  J Probst
Journal:  Chirurg       Date:  1977-01       Impact factor: 0.955

3.  Recruitment of mesenchymal stem cells and expression of TGF-beta 1 and VEGF in the early stage of shock wave-promoted bone regeneration of segmental defect in rats.

Authors:  Yeung-Jen Chen; Tilmann Wurtz; Ching-Jen Wang; Yur-Ren Kuo; Kuender D Yang; Hue-Chen Huang; Feng-Sheng Wang
Journal:  J Orthop Res       Date:  2004-05       Impact factor: 3.494

  3 in total
  2 in total

1.  [Therapy-resistant, atrophic and septic femoral pseudarthrosis].

Authors:  C Wedemeyer; R Peppmüller; T Bredendiek
Journal:  Orthopade       Date:  2011-05       Impact factor: 1.087

2.  Is non-union of tibial shaft fractures due to nonculturable bacterial pathogens? A clinical investigation using PCR and culture techniques.

Authors:  Justus Gille; Steffen Wallstabe; Arndt-Peter Schulz; Andreas Paech; Ulf Gerlach
Journal:  J Orthop Surg Res       Date:  2012-05-20       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.